Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation

被引:31
|
作者
Taha, Maie S. [1 ,2 ,3 ]
Padmakumar, Smrithi [1 ]
Singh, Amit [4 ]
Amiji, Mansoor M. [1 ]
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, 360 Huntington Ave, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Eye & Ear Infirmary, 243 Charles St, Boston, MA 02114 USA
[3] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt
[4] Puretech Hlth, 6 Tide St, Boston, MA 02210 USA
关键词
Nanomedicine; Clinical translation; Drug delivery; Challenges; Nanoparticles; Quality attributes; Quality-by-design (QbD); NANOPARTICLE SURFACE-CHARGE; DRUG-DELIVERY SYSTEMS; PROTEIN CORONA; POLYMERIC NANOPARTICLES; DESIGN APPROACH; HYBRID NANOPARTICLES; LIPID NANOPARTICLES; IN-VITRO; PHYSICOCHEMICAL PROPERTIES; INORGANIC NANOPARTICLES;
D O I
10.1007/s13346-020-00744-1
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
Nanomedicine is a rapidly emerging field with several breakthroughs in the therapeutic drug delivery application. The unique properties of the nanoscale delivery systems offer huge advantages to their payload such as solubilization, increased bioavailability, and improved pharmacokinetics with an overall goal of enhanced therapeutic index. Nanomedicine has the potential for integrating and enabling new therapeutic modalities. Several nanoparticle-based drug delivery systems have been granted approval for clinical use based on their outstanding clinical outcomes. Nanomedicine faces several challenges that hinder the realization of its full potential. In this review, we discuss the critical formulation- and biological-related quality features that significantly influence the performance of nanoparticulate systems in vivo. We also discuss the quality-by-design approach in the pharmaceutical manufacturing and its implementation in the nanomedicine. A deep understanding of these nanomedicine quality checkpoints and a systematic design that takes them into consideration will hopefully expedite the clinical translation process. Graphical abstract
引用
收藏
页码:766 / 790
页数:25
相关论文
共 50 条
  • [41] Iterating Toward Convergence: Guideline Development and the Quality of Clinical Care
    Lum, Flora
    Rapuano, Christopher J.
    Coleman, Anne L.
    OPHTHALMOLOGY, 2011, 118 (06) : 1015 - 1016
  • [42] Critical Appraisal of Clinical Trials in Multiple System Atrophy: Toward Better Quality
    Caldas, Ana Castro
    Levin, Johannes
    Djaldetti, Ruth
    Rascol, Olivier
    Wenning, Gregor
    Ferreira, Joaquim J.
    MOVEMENT DISORDERS, 2017, 32 (10) : 1356 - 1364
  • [43] Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures
    He, Hongliang
    Liu, Lisha
    Morin, Emily E.
    Liu, Min
    Schwendeman, Anna
    ACCOUNTS OF CHEMICAL RESEARCH, 2019, 52 (09) : 2445 - 2461
  • [44] Machine translation inching toward human quality
    Krikke, J
    IEEE INTELLIGENT SYSTEMS, 2006, 21 (02) : 4 - 6
  • [45] Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation
    Gu, Wenxing
    Meng, Fenghua
    Haag, Rainer
    Zhong, Zhiyuan
    JOURNAL OF CONTROLLED RELEASE, 2021, 329 (676-695) : 676 - 695
  • [46] The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
    Akin Akinc
    Martin A. Maier
    Muthiah Manoharan
    Kevin Fitzgerald
    Muthusamy Jayaraman
    Scott Barros
    Steven Ansell
    Xinyao Du
    Michael J. Hope
    Thomas D. Madden
    Barbara L. Mui
    Sean C. Semple
    Ying K. Tam
    Marco Ciufolini
    Dominik Witzigmann
    Jayesh A. Kulkarni
    Roy van der Meel
    Pieter R. Cullis
    Nature Nanotechnology, 2019, 14 : 1084 - 1087
  • [47] Beyond Human Subjects: Risk, Ethics, and Clinical Development of Nanomedicines
    Kimmelman, Jonathan
    JOURNAL OF LAW MEDICINE & ETHICS, 2012, 40 (04): : 841 - 847
  • [48] The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
    Akinc, Akin
    Maier, Martin A.
    Manoharan, Muthiah
    Fitzgerald, Kevin
    Jayaraman, Muthusamy
    Barros, Scott
    Ansell, Steven
    Du, Xinyao
    Hope, Michael J.
    Madden, Thomas D.
    Mui, Barbara L.
    Semple, Sean C.
    Tam, Ying K.
    Ciufolini, Marco
    Witzigmann, Dominik
    Kulkarni, Jayesh A.
    van der Meel, Roy
    Cullis, Pieter R.
    NATURE NANOTECHNOLOGY, 2019, 14 (12) : 1084 - 1087
  • [49] Impact of critical process parameters and critical material attributes on the critical quality attributes of liposomal formulations prepared using continuous processing
    Yenduri, Gowtham
    Costa, Antonio P.
    Xu, Xiaoming
    Burgess, Diane J.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 619
  • [50] Exploring the critical quality attributes and models of smart homes
    Luor, Tainyi
    Lu, Hsi-Peng
    Yu, Hueiju
    Lu, Yinshiu
    MATURITAS, 2015, 82 (04) : 377 - 386